Mobia Medical (NASDAQ: MOBI) — Targeting a Large, Underserved Stroke Recovery Market
Mobia Medical (NASDAQ: MOBI) trades around $14 and is one of the more interesting recent IPOs we’ve come across in the medical technology space.
The company is focused on stroke recovery, a market that affects hundreds of thousands of patients every year and remains underserved despite the significant physical limitations many survivors face long after their initial treatment.
Mobia recently debuted on the Nasdaq on May 8, pricing its IPO at $15 per share. Since then, the stock has attracted growing attention as investors evaluate the commercial potential of its lead product, Vivistim.
Vivistim is an implantable vagus nerve stimulation system designed to be used alongside rehabilitation therapy. The goal is to help improve recovery outcomes for patients suffering from chronic stroke-related impairments.
What makes the opportunity compelling is the size of the addressable market.
Approximately 800,000 strokes occur annually in the United States, and more than half of stroke survivors experience mobility limitations or other functional challenges afterward. As the U.S. population continues to age, that patient population is expected to grow over time.
According to available estimates, Vivistim could potentially address a market of roughly 1 million patients in the United States alone.
We also like the competitive positioning. Stroke recovery remains an area with relatively limited treatment alternatives, particularly for patients seeking to improve function after the initial recovery period. That creates an opportunity for differentiated technologies that can demonstrate meaningful clinical benefits.
The company is still in the early stages of its public market journey, but we think investors should pay attention to the combination of a large market opportunity, limited direct competition, and a product designed to address a significant unmet medical need.
Wall Street has also started to take notice. Goldman Sachs recently initiated coverage with a Buy rating and a $31 price target, implying roughly 130% upside from the stock’s recent closing price of $13.50.
Early-stage medical technology companies carry risk, but Mobia offers exposure to a potentially large growth opportunity in a segment of healthcare that has historically seen limited innovation. If adoption of Vivistim continues to expand, this is a company that could have a much larger footprint several years from now.
